Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Added to its challenges, Biogen is also seeing greater competitive pressures on its multiple sclerosis therapies Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), as well as blockbuster ...

Fampridine, which is approved to improve walking in MS patients, and Ocrevus may help ease walking impairments, a review of ...

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m.

Morning Bid: A deep breath before 'Liberation Day' A look at the day ahead in European and global markets from Kevin Buckland ...